These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 29974233)

  • 21. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles.
    Pham K; Li D; Guo S; Penzak S; Dong X
    J Control Release; 2016 Mar; 226():88-97. PubMed ID: 26849919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and pharmacokinetics of lopinavir in HIV/HCV coinfected patients with advanced liver disease.
    Casado JL; Del Palacio M; Moya J; Rodriguez JM; Moreno A; Perez-Elías MJ; Belso A; Dronda F; Moreno S
    HIV Clin Trials; 2011; 12(5):235-43. PubMed ID: 22180521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
    Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
    HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polyinosinic/Polycytidylic Acid-mediated changes in maternal and fetal disposition of lopinavir in rats.
    Petrovic V; Piquette-Miller M
    Drug Metab Dispos; 2015 Jul; 43(7):951-7. PubMed ID: 25887454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children.
    Bellusci CP; Rocco C; Aulicino P; Mecikovsky D; Curras V; Hegoburu S; Bramuglia GF; Bologna R; Sen L; Mangano A
    Gene; 2013 Jun; 522(1):96-101. PubMed ID: 23528223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients.
    Azoulay S; Nevers MC; Créminon C; Heripret L; Garraffo R; Durant J; Dellamonica P; Grassi J; Guedj R; Duval D
    J Immunol Methods; 2004 Dec; 295(1-2):37-48. PubMed ID: 15627609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative pharmacokinetic evaluation of lopinavir and lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model.
    Ravi PR; Vats R
    J Pharm Pharmacol; 2017 Jul; 69(7):823-833. PubMed ID: 28317117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virologic failure among children taking lopinavir/ritonavir-containing first-line antiretroviral therapy in South Africa.
    Meyers T; Sawry S; Wong JY; Moultrie H; Pinillos F; Fairlie L; van Zyl G
    Pediatr Infect Dis J; 2015 Feb; 34(2):175-9. PubMed ID: 25741970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.
    Hickman D; Vasavanonda S; Nequist G; Colletti L; Kati WM; Bertz R; Hsu A; Kempf DJ
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2911-7. PubMed ID: 15273100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
    van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
    Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of reduced maternal and fetal lopinavir exposure in a rat model of gestational diabetes.
    Anger GJ; Piquette-Miller M
    Drug Metab Dispos; 2011 Oct; 39(10):1850-9. PubMed ID: 21742899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
    Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring.
    Goicoechea M; Vidal A; Capparelli E; Rigby A; Kemper C; Diamond C; Witt MD; Haubrich R;
    Antivir Ther; 2007; 12(1):55-62. PubMed ID: 17503748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of long-term lopinavir plasma-levels in patients with liver disease.
    Langmann P; Hubert C; Heinz W; Trein A; Schnaitmann E; Leyh M; Klinker H; Winzer R
    Eur J Med Res; 2008 May; 13(5):205-8. PubMed ID: 18559302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats.
    Ravi PR; Vats R; Thakur R; Srivani S; Aditya N
    Phytother Res; 2012 Oct; 26(10):1490-5. PubMed ID: 22308076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography/tandem mass spectrometry detection.
    Estrela RC; Ribeiro FS; Seixas BV; Suarez-Kurtz G
    Rapid Commun Mass Spectrom; 2008; 22(5):657-64. PubMed ID: 18257112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.
    Calza L; Manfredi R; Trapani F; Salvadori C; Colangeli V; Borderi M; Grossi G; Motta R; Viale P
    Scand J Infect Dis; 2012 May; 44(5):381-7. PubMed ID: 22263609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained Viral Suppression in HIV-infected Children on Once-daily Lopinavir/Ritonavir in Clinical Practice.
    Gondrie IPE; Bastiaans DET; Fraaij PLA; Driessen GJA; van der Knaap LC; Visser EG; van Jaarsveld P; de Groot R; Hartwig NG; Burger DM; van Rossum AMC
    Pediatr Infect Dis J; 2017 Oct; 36(10):976-980. PubMed ID: 28475554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.
    González de Requena D; Gallego O; Valer L; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):275-8. PubMed ID: 15117450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors.
    Torti C; Uccelli MC; Quiros-Roldan E; Gargiulo F; Tirelli V; Lapadula G; Regazzi M; Pierotti P; Tinelli C; De Luca A; Patroni A; Manca N; Carosi G
    J Clin Virol; 2006 Apr; 35(4):414-9. PubMed ID: 16280255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.